Cargando…
BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
The main method of fighting against colon cancer is targeted treatment. BRAF inhibitors, which are accepted as standard treatment for V600E mutant malign melanomas, are the newest approach for targeted treatment of V600E mutant colorectal cancers. In this case report, we share our experience about t...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5925159/ https://www.ncbi.nlm.nih.gov/pubmed/29850361 http://dx.doi.org/10.1155/2018/8782328 |
_version_ | 1783318660011524096 |
---|---|
author | Peker, Yasar Subutay Can, Mehmet Fatih Ozerhan, Ismail Hakki Yagci, Gokhan Zeybek, Nazif Kavakli, Kutan Gurkok, Sedat Gozubuyuk, Alper Genc, Onur Erdem, Gokhan Ozet, Ahmet Gerek, Mustafa Peker, Yusuf |
author_facet | Peker, Yasar Subutay Can, Mehmet Fatih Ozerhan, Ismail Hakki Yagci, Gokhan Zeybek, Nazif Kavakli, Kutan Gurkok, Sedat Gozubuyuk, Alper Genc, Onur Erdem, Gokhan Ozet, Ahmet Gerek, Mustafa Peker, Yusuf |
author_sort | Peker, Yasar Subutay |
collection | PubMed |
description | The main method of fighting against colon cancer is targeted treatment. BRAF inhibitors, which are accepted as standard treatment for V600E mutant malign melanomas, are the newest approach for targeted treatment of V600E mutant colorectal cancers. In this case report, we share our experience about the use of BRAF inhibitor vemurafenib on a V600E mutant metastatic right colon adenocarcinoma patient. A 59-year-old male with only lung multiple metastatic V600E mutant right colon cancer presented to our clinic. The patient was evaluated and FOLFOX + bevacizumab treatment was initiated, which was then continued with vemurafenib. A remarkable response was achieved with vemurafenib treatment in which the drug resistance occurred approximately in the sixth month. Even though the patient benefited majorly from vemurafenib, he died on the 20th month of the diagnosis. The expected overall survival for metastatic V600E mutant colon adenocarcinoma patients is 4.7 months. BRAF inhibitors provide new treatment alternatives for V600E mutant colorectal cancers, with prolonged overall survival. BRAF inhibitors in combination with MEK inhibitors are reported as feasible treatment to overcome BRAF inhibitor drug resistance on which phase studies are still in progress. To conclude, BRAF inhibitors alone or in combination with other drugs provide a chance for curing BRAF V600E mutant colorectal cancer patients. |
format | Online Article Text |
id | pubmed-5925159 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-59251592018-05-30 BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report Peker, Yasar Subutay Can, Mehmet Fatih Ozerhan, Ismail Hakki Yagci, Gokhan Zeybek, Nazif Kavakli, Kutan Gurkok, Sedat Gozubuyuk, Alper Genc, Onur Erdem, Gokhan Ozet, Ahmet Gerek, Mustafa Peker, Yusuf Case Rep Surg Case Report The main method of fighting against colon cancer is targeted treatment. BRAF inhibitors, which are accepted as standard treatment for V600E mutant malign melanomas, are the newest approach for targeted treatment of V600E mutant colorectal cancers. In this case report, we share our experience about the use of BRAF inhibitor vemurafenib on a V600E mutant metastatic right colon adenocarcinoma patient. A 59-year-old male with only lung multiple metastatic V600E mutant right colon cancer presented to our clinic. The patient was evaluated and FOLFOX + bevacizumab treatment was initiated, which was then continued with vemurafenib. A remarkable response was achieved with vemurafenib treatment in which the drug resistance occurred approximately in the sixth month. Even though the patient benefited majorly from vemurafenib, he died on the 20th month of the diagnosis. The expected overall survival for metastatic V600E mutant colon adenocarcinoma patients is 4.7 months. BRAF inhibitors provide new treatment alternatives for V600E mutant colorectal cancers, with prolonged overall survival. BRAF inhibitors in combination with MEK inhibitors are reported as feasible treatment to overcome BRAF inhibitor drug resistance on which phase studies are still in progress. To conclude, BRAF inhibitors alone or in combination with other drugs provide a chance for curing BRAF V600E mutant colorectal cancer patients. Hindawi 2018-04-15 /pmc/articles/PMC5925159/ /pubmed/29850361 http://dx.doi.org/10.1155/2018/8782328 Text en Copyright © 2018 Yasar Subutay Peker et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Peker, Yasar Subutay Can, Mehmet Fatih Ozerhan, Ismail Hakki Yagci, Gokhan Zeybek, Nazif Kavakli, Kutan Gurkok, Sedat Gozubuyuk, Alper Genc, Onur Erdem, Gokhan Ozet, Ahmet Gerek, Mustafa Peker, Yusuf BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report |
title | BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report |
title_full | BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report |
title_fullStr | BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report |
title_full_unstemmed | BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report |
title_short | BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report |
title_sort | braf inhibitors for braf v600e mutant colorectal cancers: literature survey and case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5925159/ https://www.ncbi.nlm.nih.gov/pubmed/29850361 http://dx.doi.org/10.1155/2018/8782328 |
work_keys_str_mv | AT pekeryasarsubutay brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport AT canmehmetfatih brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport AT ozerhanismailhakki brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport AT yagcigokhan brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport AT zeybeknazif brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport AT kavaklikutan brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport AT gurkoksedat brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport AT gozubuyukalper brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport AT genconur brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport AT erdemgokhan brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport AT ozetahmet brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport AT gerekmustafa brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport AT pekeryusuf brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport |